Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 353-363

  Chapman, Kenneth R ^a   Fogarty, Charles M ^b   Peckitt, Clare ^c   Lassen, Cheryl ^c   Jadayel, Dalal ^c   Dederichs, Juergen ^d   Dalvi, Mukul ^d   Kramer, Benjamin ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Spartanburg Medical research ^*  (United States)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Breezhaler; COPD; Dose delivery; Handihaler; Preference; Use

Indexed keywords

INDACATEROL; PLACEBO; TIOTROPIUM BROMIDE; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SCOPOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARTICLE SIZE; PATIENT ASSESSMENT; PATIENT PREFERENCE; PEAK INSPIRATORY FLOW; POWDER INHALER; THERAPY EFFECT; TREATMENT DURATION; AEROSOL; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; EQUIPMENT DESIGN; HOSPITALIZATION; INHALATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT EDUCATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AEROSOLS; AGED; BRONCHODILATOR AGENTS; CANADA; CHOLINERGIC ANTAGONISTS; CROSS-OVER STUDIES; DRY POWDER INHALERS; EQUIPMENT DESIGN; FEMALE; HUMANS; INDANS; INHALATION; LUNG; MALE; MIDDLE AGED; PARTICLE SIZE; PATIENT EDUCATION AS TOPIC; PATIENT PREFERENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; QUINOLONES; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 80054094406     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S18529     Document Type: Article

References (31)

1. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371.
2. Hesselink AE, Penninx B W, Wijnhoven HA, Kriegsman DM, van Eijk JT. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scand J Prim Health Care. 2001;19(4): 255-260.
3. Vincken W, Dekhuijzen PR, Barnes P; ADMIT Group. The ADMIT series - Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J. 2010;19(1):10-20.
4. Fromer L, Goodwin E, Walsh J. Customizing inhaled therapy to meet the needs of COPD patients. Postgrad Med. 2010;122(2):83-93.
5. Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol. 2004;93(5):439-446.
6. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008; 75(1):18-25.
7. Newman S P. Inhaler treatment options in COPD. Eur Respir Rev. 2005; 14(96):102-108.
8. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593-604.
9. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(3):371-384.
10. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med. 1999;12 Suppl 1:S9-S17.
11. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulation in the therapeutic effectiveness of aerolized medications. Br J Clin Pharmacol. 2003; 56(6):600-612.
12. Janssens W, Vanden Brande P, Hardeman E, et al. Inspiratory fow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78-83.
13. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation fow with all inhalers and does training help? Respir Med. 2007;101(11):2395-2401.
14. Global initiative for chronic obstructive lung disease (GOLD). Updated 2009. At: http://www.goldcopd.com/. Accessed August 19, 2010.
15. Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005;14(7):775-783.
16. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588-599.
17. ICRP. ICRP Publication 66: Human respiratory tract model for radiological protection. A report of a task group of the International Commission on Radiological Protection. Ann ICRP. 1994;24(1-3): 1-482.
18. Global initiative for chronic obstructive lung disease (GOLD). Updated 2008. At: http://www.goldcopd.com/. Accessed August 19, 2010.
19. ® regarding preference and ease of use. J Aerosol Med. 2007;20(1):38-44.
20. Schulte M, Osseiran K, Betz R, et al. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv. 2008;21(4):321-328.
21. Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a new capsule based dry powder inhaler for the effective delivery of indacaterol. Curr Med Res Opin. 2010;26(11):2527-2533.
22. Usmani OS, Biddiscombe M F, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497-1504.
23. Barnes PJ, Basbaum CB, Nadel JA, Roberts JM. Localization of beta- adrenoreceptors in mammalian lung by light microscopic autoradiography. Nature. 1982;299(5882):444-447.
24. Fryer AD, Jacoby DB. Muscarinic receptors and control of airway smooth muscle. Am J Respir Crit Care Med. 1998;158(5 Pt 3): S154-S160.
25. Clark AR. Medical aerosol inhalers: past, present and future. Aerosol Sci Technol. 1995;22(4):374-391.
26. Newman S P, Busse W W. Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96(5):293-304.
27. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers J W, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101(7):1398-1405.
28. Van Schayck C P, Bijl-Hofand ID, Folgering H, et al. Infuence of two different inhalation devices on therapy compliance in asthmatic patients. Scand J Prim Health Care. 2002;20(2):126-128.
29. Jäger L, Laurikainen K, Leinonen M, Silvasti M. Beclomethasone dipropionate Easyhaler is as effective as budesonide Turbohaler in the control of asthma and is preferred by patients. Int J Clin Pract. 2000; 54(6):368-372.
30. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest. 2005;128(5): 3198-3204.
31. Takemura M, Mitsui K, Itotani R, et al. Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronicobstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:97-104.